{# max-image-preview:large is what makes an article eligible for the big-image card in Google Discover — without it Google may only show a thumbnail. #} {# ── Google Preferred Sources ──────────────────────────────────────────── Readers who mark us as a preferred source get our fresh articles prioritised in Top Stories, Discover and Google News. Only domain- and subdomain-level sites are eligible — blog.alfafinder.com qualifies, a /news/ subdirectory would not. #}

Biocon — Latest News

Every announcement Biocon has filed with the exchanges that we have reported, newest first. Each story links the original filing.

NSE: BIOCON BSE: 532523 Pharmaceuticals & Biotechnology 2 stories

Price

₹409.4

Market Cap

₹66,719.68 Cr

Revenue TTM

₹17,321.10 Cr

P/E (TTM)

134.71×

Sector 46.94×

Reference data from Trendlyne, as of the most recent story. Not a valuation or a recommendation.

Regulatory Approval · 1 Product Launched · 1
Regulatory Approval

Biocon Biologics Receives Japan MHLW Approval for Pegfilgrastim Biosimilar Marketing

Biocon Biologics receives Japan MHLW marketing approval for its Pegfilgrastim biosimilar. This oncology product strengthens Biocon's ₹17,321 Cr TTM r…
Product Launched

Biocon Ltd Launches Yesafili Biosimilar in US Market to Address USD 5.89 Billion Opportunity

Biocon Ltd announces the US commercial launch of Yesafili, an interchangeable biosimilar to Eylea. The product targets a US market with 19.8 million …

Track Biocon in real time

ALFA Finder watches NSE & BSE filings 24/7 and alerts you the moment Biocon files something material.

Start Free — 15-day trial
{# ── Promo popup — fires 5s after first page load per session. NEVER fires for visitors arriving from a search engine: a full-viewport overlay on a news article is an intrusive interstitial, and Google News policy is explicit that promotional material must not exceed the content. Direct, social and referral traffic still sees it. ─────────── #}